— Financial reporting — Consolidated statement of changes in equity
Consolidated statement of changes in equity
January 1 – June 30
|
|
|
|
|
Attributable to shareholders of medmix Ltd |
|
||||||||||
|
millions of CHF |
|
Notes |
|
Share capital |
|
Retained earnings |
|
Treasury shares |
|
Cash flow hedge reserve |
|
Currency translation adjustment |
|
Total equity |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Equity as of January 1, 2022 |
|
|
|
0.4 |
|
552.8 |
|
–6.5 |
|
–0.6 |
|
–12.2 |
|
533.9 |
|
|
Comprehensive income for the period: |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Net income |
|
|
|
|
|
9.2 |
|
|
|
|
|
|
|
9.2 |
|
|
– Cash flow hedges, net of tax |
|
|
|
|
|
|
|
|
|
–0.5 |
|
|
|
–0.5 |
|
|
– Remeasurements of defined benefit plans, net of tax |
|
|
|
|
|
–5.4 |
|
– |
|
– |
|
– |
|
–5.4 |
|
|
– Currency translation differences |
|
|
|
|
|
|
|
|
|
|
|
–8.0 |
|
–8.0 |
|
|
Other comprehensive income |
|
|
|
|
|
–5.4 |
|
– |
|
–0.5 |
|
–8.0 |
|
–13.9 |
|
|
Total comprehensive income for the period |
|
|
|
|
|
3.8 |
|
– |
|
–0.5 |
|
–8.0 |
|
–4.7 |
|
|
Transactions with owners of the company: |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Contribution to the Sulzer group |
|
8 |
|
|
|
–0.4 |
|
|
|
|
|
|
|
–0.4 |
|
|
Purchase of treasury shares |
|
8 |
|
|
|
|
|
–6.1 |
|
|
|
|
|
–6.1 |
|
|
Share-based payments |
|
|
|
|
|
0.8 |
|
|
|
|
|
|
|
0.8 |
|
|
Dividends |
|
8 |
|
|
|
–20.5 |
|
|
|
|
|
|
|
–20.5 |
|
|
Equity as of June 30, 2022 1) |
|
|
|
0.4 |
|
536.5 |
|
–12.5 |
|
–1.0 |
|
–20.3 |
|
503.1 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Equity as of January 1, 2023 |
|
|
|
0.4 |
|
540.3 |
|
–12.5 |
|
0.7 |
|
–24.1 |
|
504.8 |
|
|
Comprehensive income for the period: |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Net income |
|
|
|
|
|
7.3 |
|
|
|
|
|
|
|
7.3 |
|
|
– Cash flow hedges, net of tax |
|
|
|
– |
|
– |
|
– |
|
0.6 |
|
– |
|
0.6 |
|
|
– Remeasurements of defined benefit plans, net of tax |
|
|
|
– |
|
–0.3 |
|
– |
|
– |
|
– |
|
–0.3 |
|
|
– Currency translation differences |
|
|
|
– |
|
– |
– |
– |
– |
– |
– |
–3.2 |
|
–3.2 |
|
|
Other comprehensive income |
|
|
|
– |
|
–0.3 |
|
– |
|
0.6 |
|
–3.2 |
|
–2.9 |
|
|
Total comprehensive income for the period |
|
|
|
– |
|
7.0 |
|
– |
|
0.6 |
|
–3.2 |
|
4.4 |
|
|
Transactions with owners of the company: |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Sale of investments in subsidiaries |
|
|
|
– |
|
–1.7 |
|
– |
|
– |
|
– |
|
–1.7 |
|
|
Contribution to the Sulzer group |
|
8 |
|
– |
|
–0.3 |
|
– |
|
– |
|
– |
|
–0.3 |
|
|
Allocation of treasury shares to share plan participants |
|
|
|
– |
|
–0.4 |
|
0.4 |
|
– |
|
– |
|
– |
|
|
Purchase of treasury shares |
|
8 |
|
– |
|
– |
|
–1.0 |
|
– |
|
– |
|
–1.0 |
|
|
Share-based payments |
|
|
|
– |
|
1.1 |
|
– |
|
– |
|
– |
|
1.1 |
|
|
Dividends |
|
8 |
|
– |
|
–20.5 |
|
– |
|
– |
|
– |
|
–20.5 |
|
|
Equity as of June 30, 2023 |
|
|
|
0.4 |
|
525.7 |
|
–13.1 |
|
1.3 |
|
–27.3 |
|
486.9 |
|
1) The numbers as of June 30, 2022, have been adjusted following the deconsolidation of medmix Poland. A reconciliation to the previously published numbers is provided in note 14.